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ABSTRACT
Transcriptional activation by nuclear hormone
receptors is well characterized, but their coopera-
tion with other signaling pathways to activate
transcription remains poorly understood. Tumor
necrosis factor alpha (TNFa) and all-trans retinoic
acid (RA) induce monocytic differentiation of acute
promyelocytic leukemia (APL) cells in a synergistic
manner. We used the promoter of DIF2, a gene
involved in monocytic differentiation, to model the
mechanism underlying the cooperative induction of
target genes by RA and TNFa. We show a functional
RA response element in the DIF2 promoter, which is
constitutively bound by PML/RARa in APL cells. RA
stimulates release of corepressors and recruitment
of chromatin modifying proteins and additional
transcription factors to the promoter, but these
changes cause only a modest induction of DIF2
mRNA. Co-stimulation with RA plus TNFa facilitates
binding of NF-iB to the promoter, which is crucial
for full induction of transcription. Furthermore, RA
plus TNFa greatly enhanced the level of RNA Pol II
phosphorylation on the DIF2 promoter, via synergis-
tic recruitment of TFIIH. We propose that RA
mediates remodeling of chromatin to facilitate
binding of transcription factors, which cooperate
to enhance Pol II phosphorylation, providing a
mechanism whereby nuclear receptors interact
with other signaling pathways on the level of
transcription.
INTRODUCTION
Nuclear receptor mediated transcription is a multi-step
process involving an allosteric change in receptor con-
formation followed by an exchange of corepressors and
histone deacetylases (HDACs) for coactivators with
histone acetyl transferase (HAT) activity (1). These
co-activators are thought to regulate transcription
through local histone modiﬁcations, as well as further
recruitment of complexes with ATP-dependent chromatin
remodeling activities. These actions can result in the
formation of a mature preinitiation complex and induc-
tion of target gene transcription (2). The physiological
relevance of tight control of nuclear receptor target genes
is underscored by the association of malfunctional mutant
receptors with disease, such as the link between APL and
the expression of the PML/RARa oncoprotein, which
blocks transcription of RA target genes via an increased
aﬃnity for corepressors (3,4). Pharmacologic concentra-
tions of RA release corepressors from PML/RARa,
induce transcription of RARa target genes and thereby
stimulate granulocytic diﬀerentiation.
Previously, we and others have found that RA and
TNFa can act in synergy to promote diﬀerentiation of
leukemia cells (5–7) as well as normal monocytes (8).
Other signaling pathways including that of cyclic AMP (9)
can also act in synergy with RA to achieve diﬀerentiation.
However, the exact mechanisms through which these
biologic eﬀects are achieved remain largely unknown.
A likely point of convergence for these pathways is
the synergistic activation of common target genes,
although few studies have investigated the mechanisms
whereby nuclear hormone receptor pathways synergize
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genes.
To study the mechanism of transcriptional synergy
between RA and TNFa in leukemia cells, we used the
promoter of the DIF2 gene (also known as IER3, IEX-1
or PRG1) as a model. DIF2 encodes an anti-apoptotic
protein that is speciﬁcally expressed in monocytes (10,11),
and may be directly involved in the diﬀerentiation process
stimulated by RA in combination with TNFa (5,6).
The promoter of this gene contains binding sites for
several transcription factors, including an NF-kB respon-
sive element (11,12) and a putative retinoic acid response
element (RARE) (13). In the APL cell line NB4, DIF2
induction by TNFa alone is modest, consistent with
the very limited diﬀerentiation induced by TNFa in these
cells (6).
We now present evidence that PML/RARa can bind to
the DIF2 promoter and, in the presence of RA, induce
chromatin changes associated with active transcription.
In this setting, co-treatment with TNFa induces sub-
stantial NF-kB binding, Pol II phosphorylation and gene
induction on this promoter. Importantly, similar results
were found in non-APL cells, indicating that this
mechanism is not limited to the PML/RARa oncoprotein,
but also applies to wild-type RARa.
We propose that the chromatin remodeling eﬀects of
liganded RARa can facilitate binding of transcription
factors from other signaling pathways and that the
cooperative actions of these activators direct phosphor-
ylation of Pol II, thereby stimulating a synergistic
activation of transcription.
MATERIALS AND METHODS
Cellculture andreagents
NB4 and U937 cells were cultured in RPMI-1640
supplemented with 10% FBS. Trichostatin A (TSA,
Sigma) was used at a ﬁnal concentration of 200nM. RA
(Sigma) was used at a concentration of 1mM. TNFa
(Peprotech) was used at 10ng/ml. The IKKb inhibitor
compound A (14) was used at 5mM.
Northern blotting
Ten microgram of RNA was electrophoresed on a 1%
formaldehyde agarose gel and blotted onto Zeta probe
(Bio-Rad) transfer membranes. cDNA probes were
labeled by random priming (Pharmacia-Amersham).
Hybridization and autoradiography was performed as
previously described (6). DIF2 full-length cDNA was
a kind gift of Dr G. Schmitz.
Quantitative PCR
cDNA was prepared from 5mg total RNA, using Super-
script II reverse transcriptase (Invitrogen). Quantiﬁcation
of DIF2 gene expression was performed using the Applied
Biosystems 7500 Fast Real-Time PCR System with
the following primers: 50-CGCTCTGGACCTCAGCAC
TT-30 (forward) and 50-TGTTTCTTTGTGGTTTTTCG
GATT-30 (reverse) and SYBR Green based detection.
Ampliﬁcation was performed with 40 cycles of 958C
for 15s and 608C for 60s. GAPDH was used as the
endogenous control.
Western blotting
Thirty microgram of nuclear extracts, prepared as
previously described (6), were used for western blotting
to detect nuclear p65 and Pol II protein levels. Both
antibodies were from Santa Cruz biotechnologies.
Chromatin immunoprecipitation (ChIP)
The Upstate biotechnology protocol was used with minor
modiﬁcations. A total of 2 10
6 cells were treated with
RA and/or TNFa or TSA for the indicated time periods.
Protein–DNA complexes were immunoprecipitated over-
night at 48C with antibodies against SMRT, AIB1
(Aﬃnity Bioreagents), Pol II phosphoserine-5 (Covance),
SNF5 (a kind gift of Dr G. Crabtree), CBP, HDAC1,
PML, Pol II, RARa, TBP, TFIIH (p62), p50, p65, PU.1
and SP1 (Santa Cruz), acetyl histone H4, H3 di/trimethyl-
lysine 4, dimethyl-arginine 17 (Upstate) and CARM1/
PRMT4 antibodies (a gift of Dr S. Richard). Antibody
complexes were pulled down for 4h with 60ml protein A
sepharose slurry (Upstate). To reverse the formaldehyde-
induced cross-linking, NaCl was added at a ﬁnal con-
centration of 0.2M and incubated overnight at 658C.
DNA was phenol/chloroform extracted followed by
ethanol precipitation using tRNA as a carrier. Oligonu-
cleotides used for ampliﬁcation of diﬀerent areas of the
DIF2 gene were as follows: #1a 50-GGAAATCGAGAC
CACCCTGG-30, #1b 50-CAGTCTCGTTCGGTCG
CCA 30, #2a 50-GTGAGGGATCCTGTGGCTAA-30,
#2b 50-CGGGTCCTTCTAACTCCTCC-30, #3a 50-CCT
GGGTGACAGTGAAATCC-30, #3b 50-TCAGCTCACT
GCAACCTCTG-30, #4a 50-CCACTCCTTTCCAGCCA
TTA-30, and #4b 50-GAGGCTTCATGGAAGAGT
GG-30. Primers surrounding the NF-kB site of the IL8
promoter region were as previously described (15). For
quantitative PCR, ampliﬁcation was performed using
primers 2a and 2b with 40 cycles of 958C for 15s and
608C for 60s. Input DNA was used as the endogenous
control. Each treatment was performed in duplicate,
ampliﬁcations were performed in triplicate, and results
are represented as means of six measurements  SEM.
RESULTS AND DISCUSSION
Identification ofan RAREs that maymediate enhancement
of DIF2expression by RA
By northern blotting, we showed an early induction of
DIF2 mRNA production after treatment of PML/RARa
positive NB4 cells with either RA or TNFa. Induction by
TNFa alone was signiﬁcantly stronger than with RA
alone, but co-treatment with both drugs was required for
maximal induction. Quantitative RT-PCR veriﬁed that
RA alone triggers a weak induction of DIF2 expression,
but strongly potentiates its induction by TNFa
(Figure 1A).
436 Nucleic Acids Research, 2008, Vol. 36, No. 2To identify putative RAREs in the DIF2 gene that may
mediate the eﬀects of RA, we screened 5kb upstream and
downstream of the transcriptional start site for direct
repeats (DR) of the half-site (A/G)G(G/T)TCA, using
the net-based programs CONSITE and TRANSFAC TfBlast.
The maximal deviation from the consensus sequence was
restricted to one position. Upstream of the DIF2 start site,
we identiﬁed a putative DR2 RARE at position  560
(named RARE1, Figure 1B) having the sequence
AGATCAcgAGGTCA. Two overlapping DR2 elements
were also found downstream of the start site, at position
+4912 (named RARE2). Of note, a putative NF-kB site
was found close to RARE1, at position  140, while no
NF-kB site was found in the vicinity of RARE2. By ChIP
analysis using antibodies selective for RARa or PML, we
showed that PML/RARa associates with RARE1 in vivo.
The receptor was found to be constitutively bound to this
site and the presence of ligand did not alter the association
(Figure 1C). EMSA experiments also showed PML/
RARa binding to this sequence in vitro (data not
shown). In contrast, no association of PML/RARa with
RARE2 was detected, in the absence or presence of RA
(Figure 1C). Using primers speciﬁc to an area 3kb
upstream of the DIF2 start site and primers to a region
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Figure 1. TNFa and RA cooperate to activate DIF2 transcription. (A) Northern blot showing DIF2 mRNA levels in response to RA and TNFa.
T+R designates co-treatment with TNFa and RA. The graph to the right shows relative induction of DIF2 as determined by Q-PCR of NB4 cells
treated for 1h. (B) Overview of the DIF2 promoter region showing putative transcription factor binding sites. Arrows represent position of primers
employed in ChIP experiments. Underlined bases indicate deviations from a perfect, consensus RARE sequence (C) ChIP assays showing association
of PML/RARa with RARE1, but not RARE2, in the DIF2 promoter. Immunoprecipitation with mouse or rabbit IgG was used as a control
for antibody speciﬁcity. Primers encompassing a region 3kb upstream of the DIF2 start site and chromosome six primers corresponding to a region
nonadjacent to the DIF2 gene were used to show speciﬁcity of the ampliﬁcation.
Nucleic Acids Research,2008, Vol. 36,No. 2 437of chromosome six nonadjacent to the DIF2 gene, we
conﬁrmed speciﬁcity of the PML/RARa association with
RARE1 (Figure 1C).
RArecruits co-activators andchromatin modifying
complexes to theDIF2promoter region and induces
changes associated withactive transcription
Having established that DIF2 is cooperatively induced by
RA and TNFa within 1h, we deemed it to be a useful
model system to investigate the mechanism whereby the
two pathways integrate on a transcriptional level. Since
PML/RARa was found constitutively bound to RARE1
in the DIF2 promoter, and RA induced some transcrip-
tion, we ﬁrst investigated the ability of RA to recruit
diﬀerent co-stimulatory molecules to this promoter region.
RA stimulation has been demonstrated to recruit co-
activators and chromatin modifying activity to RAR
target genes within 2h (16–18), and in agreement with this,
we found that the corepressor SMRT dissociated from the
DIF2 promoter and was replaced by co-activators CBP,
TRAP220 (MED1) and ACTR (AIB1, p/CIP, SRC3)
within 1h of RA treatment (Figure 2A). These changes
further veriﬁed the presence of a functional RARE in the
promoter. We did not ﬁnd the histone methyltransferase
CARM1 to be recruited to the promoter, nor was its
target, arginine 17 of histone 3, methylated upon RA
stimulation (data not shown). This is consistent with
a previous report suggesting that CARM1 or ACTR are
recruited to the oestrogen receptor in mutually exclusive
complexes (19).
A previous study using in vitro reconstituted chromatin
found an ordered recruitment of protein complexes to the
RARa prior to transcriptional activation (20). It was
found that components of the SWI/SNF complex could
also augment RAR-driven transcription when added to
the reaction subsequent to complexes having acetyl-
transferase activity. Therefore, we looked at SWI/SNF
association with the DIF2 promoter in response to RA,
using antibodies toward the SNF5 catalytic subunit of the
complex. The chromatin remodeler was seen complexed
with the DIF2 promoter within 45min of RA treatment
and its binding was inversely correlated with the repressor
HDAC1 (Figure 2B). Interestingly, SNF5 cycled on and
oﬀ the DIF2 promoter in a manner similar to that
previously reported for the BRG1 component of the same
complex on the oestrogen-responsive pS2 promoter (19).
These data indicate that activation of PML/RARa results
in cycling of corepressors and activator proteins, as has
been observed with wild-type nuclear receptors (18,21). Of
note, even though the DIF2 promoter displayed many
aspects of a transcriptionally active gene upon RA
treatment, only a modest increase in mRNA was observed
in the absence of TNFa (Figure 1A), indicating that
chromatin remodeling in response to RA is not enough
to fully activate transcription of this gene.
To further address this issue, we investigated the
functionality of the co-activators recruited by RA. We
found a functional HAT complex to be recruited by RA as
evidenced by a marked increase in levels of histone
acetylation surrounding RARE1 (Figure 2C, left panel).
Histone acetylation was observed shortly after recruitment
of the histone acetyltransferase CBP and concurrently
with SNF5 recruitment to the DIF2 promoter (Figure 2B
and C), consistent with a previous report showing that
SWI/SNF can augment RARa induction of transcription
on chromatin templates when added subsequent to histone
acetylation (20). Studies in yeast have also indicated that
recruitment of the SWI/SNF complex may require histone
acetylation (22). Of note, ampliﬁcation with primers 3a, b
and 4a, b detected no increase in histone acetylation
around RARE2 or further upstream of the DIF2 start site
(data not shown). We further assessed changes in histone
lysine methylation after 45min of RA treatment, when
acetylation was seen to be increased. In contrast to reports
showing an increase in H3 lysine 4 methylation upon RA
stimulation (23), we observed a decrease in dimethylated
H3 lysine 4 without an increase in trimethylated H3 lysine
4 (Figure 2C, right panel, and data not shown). This is
similar to what was seen in a xenopus oocyte system with
the thyroid receptor (24). A recent report also demon-
strated that recruitment of histone demethylases and a
transient decrease in histone methylation is required for
ligand-dependent induction of transcription by nuclear
receptors (25).
The above data demonstrate that RA activation of
DIF2 in NB4 cells is associated with the induction of many
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Figure 2. RA treatment leads to cofactor exchange on the DIF2
promoter. (A) Chromatin was isolated from NB4 cells treated with RA
as indicated, and ampliﬁcations of ChIP product using primers 1a,b
show that RA stimulation leads to recruitment of ACTR, TRAP220
and CBP to the DIF2 upstream region while causing a release of
SMRT. (B) ChIP analysis demonstrating inverse temporal cycling
of SNF5 and HDAC1 in response to RA. (C) ChIP analysis of
speciﬁc histone modiﬁcations showing an increase in H4 acetylation
and a concurrent decrease in H3K4 methylation after 45min of RA
treatment.
438 Nucleic Acids Research, 2008, Vol. 36, No. 2hallmarks of a fully transcriptionally active promoter and
are consistent with previous reports of nuclear receptor
function on their target promoters.
To determine if histone acetylation is suﬃcient for
SNF5 recruitment and synergy with TNFa, we asked
whether HDAC inhibition by TSA could recapitulate
the eﬀects of RA. TSA stimulation increased both
histone 4 acetylation and SNF5 recruitment, as expected
(Figure 3A). However, northern blotting showed that
TSA did not signiﬁcantly increase DIF2 mRNA levels
when combined with either RA or TNFa, indicating that
an increase in total acetylation on this promoter, such as is
seen as a result of either RA or TSA action, cannot alone
mediate synergy with TNFa (Figure 3B). Other HDAC
inhibitors were also tested, with similar results (data not
shown).
RAfacilitates recruitment of NF-iB byTNFawithout
altering nuclear translocation ofp65/RelA
Induction of transcription by TNFa is mediated by the
transcription factor NF-kB (26). In unstimulated cells, the
NF-kB complex is sequestered in the cytoplasm by IkB
proteins. Upon TNFa stimulation, IkB is rapidly phos-
phorylated by IkB kinase beta (IKKb) and subsequently
degraded, thereby allowing release and activation of the
NF-kB complex. Activated NF-kB translocates into the
nucleus where it binds DNA and activates transcription
(27). TNFa-induced transcription is thus dependent on
IKKb and can be inhibited by a selective inhibitor, such
as compound A (14). To test if the eﬀect of RA on DIF2
transcription is also dependent on NF-kB/IKKb,w e
assessed induction of DIF2 expression by RA and/or
TNFa in the absence or presence of compound A. As
expected, the inhibitor completely blocked induction of
DIF2 by TNFa. In contrast, it had no eﬀect on RA-
induced expression, but reduced the superinduced levels
seen with RA plus TNFa to that seen with RA alone
(Figure 4A). Thus, RA action on the DIF2 promoter
appears to be independent of NF-kB, while augmenting
the NF-kB-dependent activity of TNFa. Interestingly,
a recent paper presented a detailed study of the HAS2
(hyaluronan synthase 2) promoter, which like the DIF2
promoter contains binding sites for both RARa and
NF-kB, as well as SP1 (28). Treatment with either RA or
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moter. In addition, both drugs increased HAS2 mRNA in
an NF-kB-dependent manner, but co-treatment did
not provide any additive eﬀect (28). This may suggest
that the NF-kB independent activity of RA on the DIF2
promoter is crucial for its ability to cooperate with TNFa
to induce transcription.
We therefore investigated whether RA can stimulate
binding of NF-kB transcription factors to the DIF2
promoter. We found that neither RA nor TNFa alone
could stimulate a detectable increase in binding of the NF-
kB subunits p50 and p65 to the NF-kB site found at –140
(Figure 1B). However, RA plus TNFa caused a large
increase in binding of both p50 and p65 to this site
(Figure 4B), while no increased binding to another NF-kB
site located at –3kb was observed (data not shown). This
increase could not be explained by enhanced nuclear
shuttling of NF-kB, as levels of p65 in the nucleus were
found to be equal in cells treated with TNFa alone versus
RA plus TNFa (Figure 4C). The lack of an observable
increase in NF-kB promoter binding induced by TNFa
alone was surprising, as TNFa stimulation of NB4 cells
does result in an accumulation of p65 in the nucleus, and
also a signiﬁcant increase in DIF2 mRNA. This failure to
fully activate NF-kB binding is promoter dependent, since
TNFa alone stimulates p65 binding to the IL-8 promoter
in NB4 cells (Figure 4D).
RAstimulates binding of unrelated transcription factorsto
theDIF2promoter
As shown in Figure 1B, the DIF2 promoter region has
several putative transcription factor binding sites. Since
we found that RA could stimulate TNFa-induced binding
of NF-kB, we hypothesized that RA-induced histone
modiﬁcations and SNF5 recruitment result in a change of
chromatin conformation that facilitates transcription
factor binding in general. Indeed, RA activation of the
DIF2 promoter resulted in increased binding of both PU.1
and SP1 within 1h of treatment (Figure 5A). These results
indicate that RA stimulation facilitates transcription
factor binding over a range encompassing the RARE
and further downstream, proximal to the transcription
start site. Mechanistically, these data support the idea that
integration of TNFa and RA signals lead to binding of
transcriptions factors including PML/RARa, PU.1, SP1
and NF-kB that may interact to form a fully mature
enhancesome, which is apparently NF-kB dependent. This
is similar to another NF-kB target, BFL1, where c-Rel,
c-Jun, C/EBP beta and HMG-IC cooperate in an NF-
kB-dependent manner to activate transcription (29).
RAand TNF synergistically recruit TFIIHand stimulate
phosphorylation ofRNA polymerase II
We next investigated how the coordinated recruitment
of diﬀerent transcription factors, in association with
co-activators and chromatin-modifying enzymes, can
promote transcriptional synergy. A likely candidate
would be enhanced recruitment of basal transcription
factors such as TBP or RNA Polymerase II (Pol II). ChIP
analysis showed a low level of TBP bound to the DIF2
promoter in untreated NB4 cells. RA and TNFa both
increased this binding, but a synergistic recruitment of
TBP by the two drugs together was only observed after
120min of treatment, well after a signiﬁcant enhancement
of transcription is seen (Figure 5B). Pol II was undetect-
able at the DIF2 promoter in untreated cells, but was
recruited by either RA or TNFa, within 30min
(Figure 5B). RA plus TNFa induced a slight increase in
Pol II recruitment, however, similar to TBP, a synergistic
increase was not detected until 120min post-treatment.
Thus, enhanced recruitment of Pol II may partially
explain how RA and TNFa cooperate to stimulate DIF2
transcription, and synergistic recruitment of both TBP
and Pol II after 120min may further explain how
transcription is maintained for a longer time in the
presence of both drugs (Figure 1A and data not shown).
Of note, the recruitment of TBP and Pol II seen in
response to RA or TNFa was cyclical and showed similar
kinetics to SNF5 recruitment. These data are consistent
with previous reports that found cyclical recruitment of
co-activators and the polymerase complex in response
to oestrogen, corresponding with progressive rounds of
transcription (19). PML/RARa itself was not found to
cycle, but was constitutively bound to the promoter,
independently of ligand, at all time points tested
(Figure 1C and data not shown). It is thus not clear
what is the role of the receptor itself in the cycling process.
We postulate that at the end of each round of transcrip-
tion, represented in our data by the 90min-time-point,
there is an exchange of ligand bound for unliganded
receptor, a release of co-activators and transcriptional
machinery (Figure 5B), and re-recruitment of corepres-
sors, including HDAC1 (Figure 2B). We base this model
on previous studies, which have shown that proteasomal
degradation and ‘recycling’ of nuclear receptors as well as
transcriptional cofactors are required for transcriptional
activation and probably occur at each round of transcrip-
tion (30–32).
Phosphorylation of the C-terminal repeat (CTR) of Pol
II plays a crucial role in transcriptional elongation and
it has been reported that a mature enhancesome (33) or
NF-kB binding (15) can stimulate Pol II phosphorylation.
Therefore, we investigated the status of Pol II phosphor-
ylation at the DIF2 promoter, postulating that this may
be a target of synergistic activation. Despite the fact
that both drugs increased the total level of Pol II at
the promoter, we could detect no increase in serine
5-phosphorylated Pol II in NB4 cells treated for 1h with
either RA or TNFa alone. In contrast, the combination of
TNFa and RA caused a signiﬁcant increase, indicating a
potential synergistic action of the two drugs at this level
(Figure 5C). Concurrently, with this increase in phosphor-
ylation, we observed a recruitment of the p62 subunit of
the Pol II kinase TFIIH (Figure 5C), which represents a
mechanism whereby Pol II phosphorylation and, in turn, a
heightened rate of elongation may occur in response to the
combination of TNFa and RA. Taken together, our data
suggest that although the combination of RA and TNFa
may increase the recruitment of Pol II to the DIF2
promoter, the main cooperation exerted by these drugs
occur at the level of TFIIH recruitment and Pol II
440 Nucleic Acids Research, 2008, Vol. 36, No. 2phosphorylation. We postulate that this phosphorylation
is stimulated via the recruitment of several transcription
factors by RA, and dependent on the recruitment of
NFkB, which occurs only in the presence of both RA and
TNFa.
Finally, we asked the important question whether
enhanced transcription of DIF2 and the synergistic Pol
II phosphorylation observed at the DIF2 promoter in NB4
cells is dependent on the presence of the APL-speciﬁc
PML/RARa oncoprotein, and thus limited in generality.
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Figure 5. RA stimulation facilitates transcription factor binding and synergistically enhance Pol II phosphorylation in combination with TNFa in
both APL and non-APL cells. (A) ChIP showing that RA stimulation of NB4 cells increases PU.1 and SP1 binding to the DIF2 upstream region
within 1h of RA treatment. (B) ChIP showing regulation of Pol II and TBP recruitment and cycling of these factors on and oﬀ the promoter.
NB4 cells were treated as indicated. Bottom panel: Results at 60min were analyzed by Q-PCR, as indicated in the Materials and Methods section.
(C) A synergistic enhancement of Pol II phosphorylation and recruitment of the TFIIH component p62 by RA and TNFa at 1h post treatment was
shown in NB4 cells by ChIP. Bottom panel: Q-PCR analysis of phospho-Pol II binding. (D) Top panel: Q-PCR showing DIF2 mRNA induction by
RA and TNFa in U937 PML/RARa negative, monoblastic cells. Bottom panel: ChIP analysis of phosphorylated Pol II at the DIF2 promoter in
U937 cells showing increased levels in response to TNFa and RA co-treatment.
Nucleic Acids Research,2008, Vol. 36,No. 2 441Notably, we found a similar induction of DIF2 mRNA
by RA plus TNFa in the PML/RARa negative mono-
blastic cell line U937, with a concurrent increase in Pol II
phosphorylation (Figure 5D). These data suggest a
general model for the integration of TNFa and RA
signaling, whereby the two pathways contribute to a
mature transcriptional platform (enhancesome) that facil-
itates eﬃcient Pol II phosphorylation. This requirement of
two simultaneous signals for transcriptional activation
may provide an additional means of spatial and temporal
gene regulation and may represent a novel mechanism
whereby various signaling pathways can integrate to
induce transcription.
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